

Supplementary Table 1: Description of adverse events**(1st Aging Trial)**

Event no.	Description of AR	Severity	Relation to product	Onset date	Action taken	Outcome
1	Chalazion (right eye)	mild	none	Day 15	dose not changed	recovered without sequelae
2	Skin irritation: erythema, papules (right arm)	mild	none (code B)	Day 55	test product withdrawn	recovered without sequelae
3	Skin irritation: erythema, papules (left arm)	mild	none (code A)	Day 55	test product withdrawn	recovered without sequelae
4	Headache	moderate	none	Day 4	dose not changed	recovered without sequelae
5	Covid-19 infection: sore throat, headache, limb pain	mild	none	Day 9	dose not changed	recovered without sequelae
6	Skin irritation: erythema, papules, little open wounds, itching (left arm)	mild	none (code B)	Day 51	dose not changed	recovered without sequelae
7	Skin irritation: patchy erythema (left arm)	mild	none (code B)	Day 36	dose not changed	recovered without sequelae
8	Tissue edema	mild	none (code B)	Day 20	dose not changed	condition improving

Of the eight adverse reactions documented in five subjects during the conduct of this study, **none were classified as being serious, and none were deemed related to the test products or placebo.**

(2nd Aging Trial)

All adverse reactions that occurred in this study are presented in the following table:

Event no.	Description of AR	Severity	Relation to product	Onset date	Action taken	Outcome
1	Skin irritation: erythema, papules, itching	Mild	None	Day 15	Dose not changed	Recovered without sequelae
2	Skin irritation: erythema	Mild	Probable	Day 15	Dose not changed	Recovered without sequelae
3	Skin irritation: itching	Mild	Probable	Day 29	Dose not changed	Recovered without sequelae
4	Skin irritation: burning	Mild	Probable	Day 1	Dose not changed	Recovered without sequelae

Four adverse reactions occurred as varying forms of skin irritation, including erythema, papules, itching and burning. Of the four adverse reactions documented in three subjects during the conduct of this study, all were classified as being of mild severity. In all cases, the dosage of the effected test products remained unchanged and all subjects recovered without sequelae